Walter Menzel

Prostate Management Diagnostics, Inc. engages in the provision of research and test of fluid-based screening tool to identify patients at risk of prostate cancer. It performs research on a series of genetic markers that could determine whether a prostrate cancer is indolent or aggressive in patients newly diagnosed with the disease. The company was founded by Christopher B. Ehrlich and Douglas C. Fisher in 2014 and is headquartered in Sausalito, CA.

Prostate Management Diagnostics, Inc. engages in the provision of research and test of fluid-based screening tool to identify patients at risk of prostate cancer. It performs research on a series of genetic markers that could determine whether a prostrate cancer is indolent or aggressive in patients newly diagnosed with the disease. The company was founded by Christopher B. Ehrlich and Douglas C. Fisher in 2014 and is headquartered in Sausalito, CA.

Peter Michael Foundation supports prostate cancer patients. It discovers and underwrites tools and technologies for the identification, treatment, and management of prostate cancer. The company was founded by Walter B. Menzel in 2004 and is headquartered in Sausalito, CA.

Prostate Management Diagnostics, Inc. engages in the provision of research and test of fluid-based screening tool to identify patients at risk of prostate cancer. It performs research on a series of genetic markers that could determine whether a prostrate cancer is indolent or aggressive in patients newly diagnosed with the disease. The company was founded by Christopher B. Ehrlich and Douglas C. Fisher in 2014 and is headquartered in Sausalito, CA.

Prostate Management Diagnostics, Inc. engages in the provision of research and test of fluid-based screening tool to identify patients at risk of prostate cancer. It performs research on a series of genetic markers that could determine whether a prostrate cancer is indolent or aggressive in patients newly diagnosed with the disease. The company was founded by Christopher B. Ehrlich and Douglas C. Fisher in 2014 and is headquartered in Sausalito, CA.

Prostate Management Diagnostics, Inc. engages in the provision of research and test of fluid-based screening tool to identify patients at risk of prostate cancer. It performs research on a series of genetic markers that could determine whether a prostrate cancer is indolent or aggressive in patients newly diagnosed with the disease. The company was founded by Christopher B. Ehrlich and Douglas C. Fisher in 2014 and is headquartered in Sausalito, CA.